A Safety and Efficacy Study of Eltrombopag in Subjects With AML
Status:
Completed
Trial end date:
2017-01-25
Target enrollment:
Participant gender:
Summary
The purpose of this randomized, blinded, placebo-controlled study was to provide clinical
safety and exploratory efficacy data on the use of Eltrombopag in adult subjects with Acute
Myeloid Leukemia (AML) receiving standard induction chemotherapy with daunorubicin plus
cytarabine. A minimum of 120 evaluable subjects newly diagnosed with AML was stratified by
antecedent malignant hematologic disorder and age.